Tradestie Institutional Equity Comparison Engine

SYRE vs ROIV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ROIV Overall Edge

ROIV Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Roivant Sciences Ltd. Common Shares (ROIV) driven by superior Growth & Margin, Options & Structure while SYRE counters with relative strength in Momentum & Technical. Fundamentally, SYRE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ROIV at N/M Forward P/E and -3226.3% operating margin (+2135.6% YoY). In options structure, SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against ROIV sits in CONSOLIDATION (7th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SYRE N/M vs ROIV N/M Fwd P/E
Growth & Margin Winner ROIV
Op Margin 0.0% vs -3226.3% ยท YoY +0.0% vs +2135.6%
Momentum & Technical Winner SYRE
1Y +341.7% vs +88.6% ยท 52W Pos 88% vs 84%
Options & Structure Winner ROIV
UNCLASSIFIED (10th %ile IV) vs CONSOLIDATION (7th %ile IV)
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
ROIV NASDAQ
Roivant Sciences Ltd. Common Shares
Pharmaceutical Preparations
$38.77
-1.92% 1D
Market Cap $28.7B
1M Return +15.63%
1Y Return +88.57%
Forward P/E N/M
Unified AI Score
36.3 / 100 SELL
Tech 8.0 Fund 36.0 Flow 65.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SYRE +341.74% ROIV +88.57% Spread: +253.17 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SYRE TTM Op. Margin: 0.0% ROIV TTM Op. Margin: -3226.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs ROIV. Trailing 12-month operating profitability (SYRE 0.0% vs ROIV -3226.3%) and valuation multiples (SYRE N/M vs ROIV N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SYRE (2) vs ROIV (4)
Institutional Metric SYRE ROIV Criterion Row Winner
Market Capitalization Scale $9.8B $28.7B Larger Scale ROIV
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +2135.6% Higher Growth ROIV
Operating Margin (TTM) Profitability 0.0% -3226.3% Higher Margin SYRE
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -35.0% -8.5% Higher ROE ROIV
52-Week Range Position Momentum 88% ($22โ€“$111) 84% ($20โ€“$42) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.75ฮฒ ยท 59% Vol 1.04ฮฒ ยท 49% Vol Lower Realized Risk ROIV
Unified Institutional Score Composite Signal 36.1 / 100 (SELL) 36.3 / 100 (SELL) Higher Composite Tie

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SYRE vs ROIV Buy Guide
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ROIV CONSOLIDATION
48d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live ROIV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SYRE nor ROIV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.